Saltz- thx, I just would say that Combo is risk off, done deal and GvHD a very good step towards the same as well today.
Only Mono high dosage and patient screening still contains some risk regarding our 'beloved' rebound stats.
And yes, the other invisible investors and funds surely know the very same, but won't bother a low SP in the meantime.
So we get Combo FDA news soon as well as probably alternative funding, in case the next Paulson cancellation is correct.
Sidenote: Now that GvHD is an open label, they should (have) disclose(d) the related data as well .. maybe in 30+ days.
Sometimes I can't help it that company might leave the door open for cheap shares for a little while longer .. for whoever they like to please (o8>
News 
Market Data 
Discover 
